Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin‐13
- 1 August 1995
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 25 (8) , 2340-2348
- https://doi.org/10.1002/eji.1830250833
Abstract
Cytokines locally delivered to the site of a tumor boost both specific and nonspecific host anti‐tumor defenses. Interleukin (IL)‐13 is a recently described cytokine produced by mouse type 2 helper T lymphocytes. The aim of this study was to evaluate the inhibition of tumor growth induced by IL‐13 delivered locally within or around transplanted tumor cells in mice. We observed that local administration of IL‐13 at the site of transplanted tumor cells in vivo had potent inhibitory effects on growth of both immunogenic (P815 mastocytoma, H‐2d) or nonimmunogenic (3LL lung carcinoma, H‐2b) tumor cells. Mice injected with transfected P815 cells secreting large amounts of IL‐13 rejected the P815 tumor and developed systemic specific anti‐tumor immunity leading to long‐lasting specific anti‐tumor protection. Less efficient anti‐tumoral effects were obtained with the nonimmunogenic 3LL tumor model when local administration of IL‐13 was achieved by co‐inoculating xenogeneic chinese hamster ovary (CHO) IL‐13 cells. Several local injections of CHO IL‐13 cells were needed to obtain rejection of 3LL tumors and no induction of long‐lasting anti‐3LL memory was obtained. Several studies were performed to elucidate the IL‐13 anti‐tumoral effects. Experiments with nude mice indicated that IL‐13 can also stimulate nonspecific anti‐tumor defenses. The histological examination of P815 IL‐13 cells undergoing rejection showed monocytic cells and neutrophils infiltrating the tumor. Studies indicated that IL‐13 administered in vitro did not directly stimulate the cytotoxicity of peritoneal macrophages and natural killer cells. However, experiments with Boyden chemotaxis chambers indicated that IL‐13 was chemotactic for macrophages. Finally, preliminary experiments in vitro suggest that IL‐13 improved antigenic presentation of P815 membranes. Thus, anti‐tumor effects of IL‐13 in vivo most probably result from pleiotropic effects including recruitment of nonspecific cells and improved stimulation of immune‐specific anti‐tumor effectors.Keywords
This publication has 38 references indexed in Scilit:
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Interleukin‐13 stimulates interleukin‐6 production by human keratinocytesFEBS Letters, 1994
- Cancer vaccinesImmunology Today, 1993
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993
- Macrophage colony‐stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppressionEuropean Journal of Immunology, 1993
- An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4Science, 1992
- Three-Dimensional Solution Structure of Human Interleukin-4 by Multidimensional Heteronuclear Magnetic Resonance SpectroscopyScience, 1992
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivoEuropean Journal of Immunology, 1991
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989